Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Astellas US LLC et al v. Hospira, Inc.
Case Number:
1:18-cv-01675
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
- Cooley LLP
- Duane Morris
- Fish & Richardson
- Heyman Enerio
- Morris James
- Morris Nichols
- Phillips McLaughlin
- Potter Anderson
- Shaw Keller
- Young Conaway
Companies
- Apotex Inc.
- Astellas Pharma Inc.
- Curia Global Inc.
- Dr. Reddy's Laboratories Ltd.
- Gilead Sciences Inc.
- Gland Pharma Ltd.
- Glenmark Pharmaceuticals Ltd.
- Hospira Inc.
- Sun Pharmaceutical Industries Ltd.
- Wockhardt Bio AG
- Wockhardt USA LLC
Sectors & Industries:
-
September 27, 2022
Fed. Circ. Temporarily Pauses Launch Of Generic Lexiscan
The Federal Circuit imposed a temporary stay Tuesday that blocks Pfizer from launching a generic version of the coronary artery test Lexiscan, even though a Delaware federal judge ruled earlier this year that the new drug wouldn't actually infringe any patents Gilead has on Lexiscan.
-
May 20, 2022
Gilead Loses Patent Case Over Lexiscan Generic
Gilead lost its bid to shield its Lexiscan brand of cardiac stress agent from generic competition by Pfizer when the top federal judge in Delaware ruled the new drug wouldn't actually infringe any of Gilead's patents.
-
January 20, 2022
IP Forecast: Minerva, Hologic To Face Off At Fed. Circ. Again
Federal Circuit judges will consider next week whether a medical device startup's founder can attack a patent he helped develop after a U.S. Supreme Court decision in the dispute last year narrowed rules for blocking inventors from challenging their own patents.